Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer (EOC) MOST POPULAR After Losing His Mom To Breast Cancer, Man Founds ‘Not Just... September 5, 2019 A College Senior vs. A Global Pandemic September 30, 2020 How Wartime Violence Against Women Is Hurting Millions Worldwide August 2, 2021 Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia June 14, 2018 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Nirogacestat Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... EMA Recommends Granting a Marketing Authorisation for Azacitidine Survey results reveal attitudes towards cancer screening during the pandemic
